Document is current

Article History

Received: 28 October 2024

Accepted: 11 December 2024

First Online: 30 December 2024

Declarations

:

: All authors declare no financial or non-financial competing interests.

: The research was approved by the Regional Ethical Review Board of Turku University Hospital (53/1801/2020) with registry research permits (Turku CRC T186/2020, SATSHP 59/2020, VSHP 30/2020). The research use of tissue materials was granted based on Finnish legislation (the Act on the Medical Use of Human Organs, Tissues and Cells, FINLEX 21a§, 689/2012) by FIMEA (2020/006811 and 2021/003921) and, when feasible, in association with Auria Biobank, Turku, Finland (AB20-4076). The research was performed in accordance with the ethical standards of the World Medical Associations code of ethics () and the 1964 Helsinki declaration and its later amendments (). As tissue samples were used retrospectively, the need to obtain informed consent was waived. The interactive tool for estimating the risk of recurrence in neoadjuvant-treated breast cancer patients is based on the current research results. The risk estimate follows the input data given by the user as numbers or Boolean types. The process is totally anonymous, and no sensitive patient data are addressed. Calculation method applies a decision tree method, and the resulting estimate represents cumulated risk in relation to the current cohort. The tool does not use any database enabling open access. Hence, no privacy statement or data protection methods are required to meet the General Data Protection Regulation (GDPR) requirements.